Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aglatimagene Besadenovec + Valacyclovir with EBRT in Localized Prostate Cancer
NCT07332000Phase 2Recruiting
- Sponsor
- Candel Therapeutics
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of aglatimagene besadenovec in prostate cancer (PCa), sponsored by Candel Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07332000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332000.